| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 0.20 | -100 |
| Intrinsic value (DCF) | 1477.23 | 3077 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.